Journal of Pharmaceutical Investigation Earns Q1 Ranking With 5.5 Impact Factor

The Journal of Pharmaceutical Investigation, a peer-reviewed publication covering pharmaceutical sciences and drug development, has solidified its standing in the scientific literature landscape through its abstracting and indexing profile, which now places it among the most visible journals in its field. According to its publisher, Springer, the journal has been abstracted and indexed in Science Citation Index Expanded, commonly known as SciSearch, since 2021, and it recorded an Impact Factor of 5.5 in 2022. That figure corresponds to a Q1 position in the Journal Citation Reports category of Pharmacology and Pharmacy, where the journal ranked 48th out of 278 titles. For researchers, librarians, and institutions navigating an increasingly crowded publishing environment, these metrics are more than vanity numbers; they shape where scientists choose to submit their work, how funding bodies evaluate publication records, and how discoveries travel through the global research ecosystem.

Abstracting and indexing is the infrastructure that makes scientific literature discoverable. When a journal is indexed in a database such as Science Citation Index Expanded, its articles are cataloged with standardized metadata, including author names, affiliations, abstracts, keywords, and cited references. This allows search engines and bibliographic databases to retrieve the work reliably when researchers query the literature. Without such indexing, even high-quality research risks becoming effectively invisible, buried in a journal that major discovery platforms do not cover. The Science Citation Index Expanded, maintained by Clarivate as part of the Web of Science Core Collection, is one of the most selective and widely used indexes in science, and inclusion in it signals that a journal has passed editorial and quality evaluations covering publishing standards, international diversity, peer-review rigor, and citation impact.

The 2022 Impact Factor of 5.5 reflects how often articles published in the journal during 2020 and 2021 were cited in 2022, averaged across the number of substantive items published in that window. Impact Factors are calculated annually from the citation data underlying the Journal Citation Reports, and they remain the single most quoted metric in journal evaluation despite ongoing debate about their limitations. A score of 5.5 places the Journal of Pharmaceutical Investigation comfortably above the median for pharmacology journals, a field that spans basic drug discovery, formulation science, pharmacokinetics, clinical pharmacology, and regulatory science. The Q1 designation, meaning the top quartile of the category, is a threshold that many institutions use when assessing whether a publication outlet meets quality expectations for faculty evaluation, grant reporting, and doctoral training requirements.

The journal’s rise through the rankings has been relatively rapid. Its inclusion in Science Citation Index Expanded dates to 2021, meaning that within roughly two years of entering the index it climbed into the upper quarter of a competitive category containing 278 journals. Pharmacology and Pharmacy is one of the most heavily populated categories in the Journal Citation Reports, encompassing everything from specialist translational titles to large general pharmacology journals, so a rank of 48 out of 278 represents a meaningful position rather than a marginal one. Analysts of scholarly publishing note that newly indexed journals often experience a citation lag, because articles published before indexing are not captured in Impact Factor calculations and it takes time for the journal to accumulate visibility in databases that researchers consult daily. Beating that lag and reaching Q1 quickly suggests strong citation performance for the recently published work that the metric does capture.

For the pharmaceutical research community, the journal’s visibility matters in practical terms. The Journal of Pharmaceutical Investigation publishes work on drug delivery systems, pharmacokinetics and pharmacodynamics, novel formulations, nanomedicine approaches, and investigative studies bridging laboratory findings and clinical application. Researchers in these areas compete for attention in a literature that grows by hundreds of thousands of articles each year. Indexing in SciSearch ensures that their papers appear in Web of Science searches, are linked through citation networks to related work, and are counted in the bibliometric profiles that individual scientists build over their careers. Citation counts drawn from indexed databases feed into h-index calculations, institutional rankings, and the evaluation criteria of major funding agencies, so the difference between an indexed and a non-indexed journal can directly affect a researcher’s professional trajectory.

The broader context is a scholarly publishing industry undergoing rapid change. Open access models, preprint servers, and alternative metrics have diversified how research is disseminated and assessed, yet established indexes such as Science Citation Index Expanded continue to function as gatekeepers of legitimacy. Clarivate applies a multi-stage evaluation to candidate journals, examining editorial consistency, peer-review integrity, the international composition of authorship and editorial boards, citation behavior, and adherence to publishing ethics standards. Journals that fail to meet these criteria are excluded, and those already indexed face periodic re-evaluation, with titles that decline in quality or engage in citation manipulation subject to delisting. In this environment, the Journal of Pharmaceutical Investigation’s sustained inclusion and its Q1 performance indicate that its editorial processes and citation record have withstood scrutiny from the field’s most influential bibliometric authority.

Librarians and research administrators pay close attention to these indicators when making collection and policy decisions. University libraries with constrained budgets rely on indexing status and quartile rankings to decide which subscriptions to maintain, while research offices frequently maintain lists of approved outlets for publication based on Journal Citation Reports quartiles. A Q1 pharmacology journal with a 5.5 Impact Factor is likely to appear on such lists, channeling submissions toward it and reinforcing the citation cycle that sustains its metrics. Critics of this feedback loop argue that it concentrates attention on already prominent journals and can disadvantage regional or emerging titles, but the practical reality for authors is that indexing and quartile remain decisive factors in where they send their manuscripts, particularly in applied fields where industry and regulatory audiences consult the indexed literature.

The journal’s metrics also carry weight internationally, particularly in Asia, where pharmaceutical sciences research output has expanded dramatically over the past two decades. The Journal of Pharmaceutical Investigation has historically served as a venue for research from pharmacology and pharmaceutics communities across Asia and beyond, and its strengthened bibliometric profile gives authors in these regions a high-visibility home for work that might otherwise migrate to Western-centric titles. Bibliometric studies have documented the growing share of global pharmaceutical research produced in countries such as South Korea, Japan, China, and India, and journals that combine regional roots with international indexing standards are well positioned to capture this expanding output. The 2022 figures suggest that the journal is successfully converting that growth into citation impact recognized at a global level.

Looking ahead, the journal’s trajectory will depend on maintaining the editorial quality and citation performance that underpin its current standing. Impact Factors fluctuate from year to year, and a single weak publication cycle can shift a journal’s quartile position in a category as densely packed as Pharmacology and Pharmacy. At the same time, the ongoing evolution of research assessment, including movements such as the Declaration on Research Assessment that encourage evaluation beyond a single metric, may gradually change how much weight the Impact Factor carries. For now, however, the combination of Science Citation Index Expanded coverage, a 5.5 Impact Factor, and a Q1 ranking gives the Journal of Pharmaceutical Investigation a strong position in the competitive market for pharmaceutical sciences research, and a clear signal to authors and readers about the visibility their work can expect to achieve.

Subject of Research: Abstracting and indexing status and citation impact of the Journal of Pharmaceutical Investigation

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Journal Citation Reports, pharmacology, pharmacy, Q1 journal, Springer, bibliometrics, scholarly publishing